-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17

Benzinga·10/08/2026 14:10:22
Listen to the news
RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sector Perform and lowers the price target from $19 to $17.